Lung Cancer Considered podcast

ESMO 2026 Highlights – Part 2

0:00
59:27
Rewind 15 seconds
Fast Forward 15 seconds
In Part 2 of our ESMO 2026 Highlights series, Dr. Stephen Liu and Dr. Narjust Florez welcome Dr. Xiao-Rong Dong, Dr. Yi-Long Wu, and Dr. Chantal Decroisette to discuss three important clinical trials: SAFFRON, SANOVO, and PERSEE. The conversations explore emerging strategies for targeting MET in EGFR-mutated non-small cell lung cancer, advances in first-line immunotherapy, and the potential implications of these findings for clinical practice. Xiao-Rong Dong, MD, PhD ([email protected]) Professor, Chief Physician and Doctoral Supervisor Director, Department of Thoracic Oncology Cancer Center of Union Hospital, Huazhong University of Science and Technology No Social Chantal Decroisette, MD Thoracic Oncologist, Medical Oncology Department Centre Léon Bérard, Lyon No Social Yi-Long Wu, MD Professor, Guangdong Lung Cancer Institute Guangdong Provincial People’s Hospital Social: @ThomasW35874311

More episodes from "Lung Cancer Considered"